Research Topics
Species | Christopher BroderSummaryAffiliation: Uniformed Services University of the Health Sciences Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Immunization strategies against henipavirusesChristopher C Broder
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
Curr Top Microbiol Immunol 359:197-223. 2012..Several henipavirus challenge models have been used and recent successes in both active and passive immunization strategies against henipaviruses have been reported which have all targeted the viral envelope glycoproteins...- Henipavirus outbreaks to antivirals: the current status of potential therapeuticsChristopher C Broder
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, United States
Curr Opin Virol 2:176-87. 2012..Here, recent findings on the few most advanced henipavirus countermeasures are summarized and discussed... 
Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoproteinKatharine N Bossart
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
Virol J 2:57. 2005..Here, we have evaluated these peptides as well as the corresponding scrambled peptide controls in Nipah virus and Hendra virus-mediated membrane fusion and against infection by live virus in vitro...- The YPLGVG sequence of the Nipah virus matrix protein is required for buddingJared R Patch
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814, USA
Virol J 5:137. 2008..Here, we have used this system to further explore the budding process by analyzing elements within the M protein that are critical for particle release... - Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix proteinJared R Patch
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814, USA
Virol J 4:1. 2007..Here, we have established recombinant expression systems to study NiV particle assembly and budding through the formation of virus-like particles (VLPs)... - Expression of Human CD4 and chemokine receptors in cotton rat cells confers permissiveness for productive HIV infectionJorge C G Blanco
Virion Systems Inc, 9610 Medical Center Drive, Suite 100, Rockville, Maryland 20850, USA
Virol J 6:57. 2009.... - A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay systemDimple Khetawat
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814, USA
Virol J 7:312. 2010.... - Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor bindingKimberly A Bishop
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
J Virol 82:11398-409. 2008..Together, these data suggest the stalk domain of G plays an important role in the conformational stability and receptor binding-triggered changes leading to productive fusion, such as the dissociation of G and F... - Identification of Hendra virus G glycoprotein residues that are critical for receptor bindingKimberly A Bishop
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
J Virol 81:5893-901. 2007.... - Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virusKatharine N Bossart
Department of Microbiology and Immunology, F Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814 4799, USA
J Virol 79:6690-702. 2005..This HeV sG glycoprotein will be exceedingly useful for structural studies, receptor identification strategies, and vaccine development goals for these important emerging viral agents... - Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunizationPeng Fei Zhang
Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
Proc Natl Acad Sci U S A 104:10193-8. 2007..Neutralization was IgG-mediated and HIV-1-specific. These results demonstrate that induction of truly broad spectrum neutralizing antibodies is an achievable goal in HIV-1 vaccine development... - Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cellsGerald V Quinnan
Department of Preventive Medicine and Biometrics, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814, USA
J Virol 79:3358-69. 2005..Induction of cross-reactive, primary HIV-1-neutralizing antibodies is feasible and, when potent, may result in complete protection against infection with a heterologous challenge virus strain... - Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccineBruce A Mungall
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
J Virol 80:12293-302. 2006..These results indicate that the cat provides a consistent model for acute NiV infection and associated pathogenesis and an effective subunit vaccine strategy appears achievable... - Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virusMatthew I Bonaparte
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA
Proc Natl Acad Sci U S A 102:10652-7. 2005..Together, these data indicate that EFNB2 serves as a functional receptor for both HeV and NiV. The highly conserved nature of EFNB2 in humans and animals is consistent with the broad tropism exhibited by these emerging zoonotic viruses... 
Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entryIngrid Markovic
Center for Drug Evaluation and Research, Food and Drug Adminiatration, Bethesda, MD, USA
Blood 103:1586-94. 2004....- Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteinsKatharine N Bossart
Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814, USA
J Virol 76:11186-98. 2002..However, no heterotypic activity was observed with envelope glycoproteins of the morbilliviruses Measles virus and Canine distemper virus... - The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophagesTzanko S Stantchev
Department of Microbiology and Immunology, F Edward Hebert School of Medicine, Uniformed Services University Bethesda, 4301 Jones Bridge Road, MD 20814, USA
Virus Res 123:178-89. 2007..These findings suggest that other exploitable targets, or steps, of the HIV-1 infection process may exist and could serve as additional opportunities for the development of new therapeutics... - Preparation of recombinant viral glycoproteins for novel and therapeutic antibody discoveryYee Peng Chan
Uniformed Services, University of the Health Sciences, Bethesda, MD, USA
Methods Mol Biol 525:31-58, xiii. 2009.... - Functional studies of host-specific ephrin-B ligands as Henipavirus receptorsKatharine N Bossart
CSIRO Livestock Industries, Australian Animal Health Laboratory, Geelong, Victoria 3220, Australia
Virology 372:357-71. 2008.... - Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibodyZhongyu Zhu
Protein Interactions Group, Center for Cancer Research Nanobiology Program, Center for Cancer Research, National Cancer Institute Frederick, National Institutes of Health, Frederick, MD 21702 1201, USA
J Infect Dis 197:846-53. 2008..These results suggest that m102.4 has potential as a therapeutic agent for the treatment of diseases caused by henipaviruses. It could be also used for prophylaxis and diagnosis, and as a research reagent... - Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigensMei Yun Zhang
CCRNP, CCR, NCI Frederick, NIH, Bldg 469, Rm 131, P O Box B, Miller Drive, Frederick, MD 21702 1201, USA
J Virol 82:6869-79. 2008..Its novel conserved conformational epitope on gp41 could be helpful in the design of vaccine immunogens and as a target for therapeutics... - A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in catsJennifer A McEachern
CSIRO Livestock Industries, Australian Animal Health Laboratory, 5 Portarlington Road, Geelong, Victoria 3220, Australia
Vaccine 26:3842-52. 2008..The ability to elicit protective systemic and mucosal immunity in this animal model provides significant progress towards the development of a human subunit vaccine against henipaviruses... - Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3Kai Xu
Structural Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Proc Natl Acad Sci U S A 105:9953-8. 2008..The structures further suggest that the NiV-G/ephrin interactions can be effectively targeted to disrupt viral entry and provide the foundation for structure-based antiviral drug design... - Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteinsDiana I Albu
Center for Immunology and Microbial Disease, Albany Medical College, Albany, New York 12208, USA
J Virol 77:5589-97. 2003.... - Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicityXiaodong Xiao
Laboratory of Experimental and Computational Biology, National Cancer Institute Frederick, NIH, Bldg 469, Rm 246, P O Box B, Miller Drive, Frederick, MD 21702 1201, USA
Vaccine 21:4275-84. 2003..These findings suggest that stable purified Env-CD4-CCR5(CXCR4) complexes can be produced in relatively large amount sufficient for their further characterization that may help in the development of novel vaccines candidates... - Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entryAngelo Gallina
Department of Pathology and Microbiology, Boston University School of Medicine, Boston, Massachusetts 02118, USA
J Biol Chem 277:50579-88. 2002..Conformational changes resulting from the opening of gp120-disulfide loops may drive the processes of virus-cell and cell-cell fusion. The biochemical events described identify new potential targets for anti-HIV agents... - Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display libraryMei Yun Zhang
Laboratory of Experimental and Computational Biology, CCR, NCI Frederick, NIH, Bldg 469, Rm 246, P O Box B, Miller Drive, Frederick, MD 21702 1201, USA
J Immunol Methods 283:17-25. 2003..The methodology and the results may have implications for development of HIV vaccines and inhibitors, as well as for identification of antibodies to conserved epitopes on rapidly mutating viruses and cells... - Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related virusesZhongyu Zhu
Protein Interactions Group, CCRNP, BRP, SAIC Frederick, Inc, NCI Frederick, NIH Bldg 469, Rm 139, PO Box B, MD 21702 1201, USA
Expert Rev Anti Infect Ther 4:57-66. 2006.... - Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodiesVidita Choudhry
Protein Interactions Group, CCRNP, NCI Frederick, NIH, Frederick, MD 21702, USA
Virology 363:79-90. 2007.... - Viral glycoprotein-mediated cell fusion assays using vaccinia virus vectorsKatharine N Bossart
Department of Microbiology and Molecular Genetics, Medical College of Wisconsin, Milwaukee, WI, USA
Methods Mol Biol 269:309-32. 2004..This chapter will detail the methods of the vaccinia virus-based reporter-gene fusion assay and how it may be used to characterize the fusion mediated by the BSL-4-classified Hendra and Nipah viruses... - Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panningMei Yun Zhang
Protein Interactions Group, CCRNP, CCR, NCI Frederick, NIH, Frederick, Maryland 21702, USA
J Immunol Methods 317:21-30. 2006..These results may have implications for the selection of novel gp41-specific bcnAbs and other antibodies, and for the development of HIV-1 inhibitors and vaccine immunogens... - Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibodyMei Yun Zhang
Human Immunovirology Group, Laboratory of Experimental and Computational Biology, Center for Cancer Research, National Cancer Institute Frederick, NIH, Frederick, Maryland 21702 1201, USA
J Virol 78:9233-42. 2004.... - Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexesMaxime Moulard
Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA
Proc Natl Acad Sci U S A 99:6913-8. 2002.... - Developments towards effective treatments for Nipah and Hendra virus infectionKatharine N Bossart
Australian Animal Health Laboratory, CSIRO Livestock Industries, Geelong, Victoria 3220, Australia
Expert Rev Anti Infect Ther 4:43-55. 2006.... - Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodiesZhongyu Zhu
CCRNP, CCR, NCI-Frederick, NIH, Frederick, MD 21702, USA
J Virol 80:891-9. 2006.... - Hendra and Nipah viruses: pathogenesis and therapeuticsBryan T Eaton
Australian Animal Health Laboratory, CSIRO, 5 Portarlington Road, Geelong, Victoria 3220, Australia
Curr Mol Med 5:805-16. 2005.... - Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogensYen-Hung Chow
Laboratory of Experimental and Computational Biology, National Cancer Institute-Frederick, NIH, Miller Drive, Frederick, Maryland 21702-1201, USA
Biochemistry 41:7176-82. 2002..Thus, tethered Envs with long linkers may not only be important as HIV-1 inhibitors but also for elucidation of viral entry mechanisms and development of novel vaccine immunogens... - Marked structural and functional heterogeneity in CXCR4: separation of HIV-1 and SDF-1alpha responsesAndrew J Sloane
HIV Protein Interactions Laboratory, Centre for Virus Research, Westmead, NSW, Australia
Immunol Cell Biol 83:129-43. 2005..This separation of structure and function has implications for understanding HIV-1 entry and SDF-1alpha responses and may indicate therapeutic possibilities... - Vertical transmission and fetal replication of Nipah virus in an experimentally infected catBruce A Mungall
Commonwealth Scientific and Industrial Research Organisation, Livestock Industries, Australian Animal Health Laboratory, Geelong, Victoria, Australia
J Infect Dis 196:812-6. 2007.... - Hendra and Nipah viruses: different and dangerousBryan T Eaton
Australian Animal Health Laboratory, Commonwealth Scientific and Industrial Research Organization, 5 Portarlington Road, Geelong, Victoria 3220, Australia
Nat Rev Microbiol 4:23-35. 2006.... - Cell adhesion promotes Ebola virus envelope glycoprotein-mediated binding and infectionDerek Dube
Department of Microbiology, University of Virginia, 1300 Jefferson Park Ave, Charlottesville, Virginia 22908 0734, USA
J Virol 82:7238-42. 2008..Furthermore, with 293F cells the acquisition of EboV RBD binding paralleled cell spreading and did not require new mRNA or protein synthesis...
Research Grants
- Nipah Virus and Hendra Virus Entry and Virion AssemblyChristopher Broder; Fiscal Year: 2009....
- Nipah Virus and Hendra Virus Entry and Virion AssemblyChristopher Broder; Fiscal Year: 2007....
- HIV-1 Fusion CoreceptorsChristopher Broder; Fiscal Year: 2007..abstract_text> ..
- Nipah Virus and Hendra Virus Subunit VaccinesChristopher Broder; Fiscal Year: 2006..We will evaluate monoclonal and polyclonal antibodies in both reporter-gene membrane fusion assays and in virus-neutralization assays. ..
- Nipah virus and Hendra virus Peptide TherapeuticsChristopher Broder; Fiscal Year: 2006..We will establish the required experimental conditions and parameters and test this hypothesis in a NiV infection model using the cat. ..
- HIV-1 FUSION COFACTORSChristopher Broder; Fiscal Year: 2002....
- Nipah Virus and Hendra Virus Entry and Virion AssemblyChristopher Broder; Fiscal Year: 2010....